THURSDAY, June 27, 2019 -- Children of mothers who are often exposed to solvent chemicals in the workplace appear to have an increased risk of autism, a new study finds.
The study of almost 1,000 families can't prove cause and effect, but researchers report that mothers of autistic children had more frequent exposure to solvents than mothers of children without autism. Overall, moms exposed to solvents were 1.5 times more likely to have a child with autism.
TUESDAY, July 23, 2019 -- Lots of kids are picky eaters. But when eating habits in young children are extreme, it could be a sign of autism, researchers say.
A new study finds atypical eating behaviors -- such as hypersensitivity to food textures or pocketing food without swallowing -- in 70% of kids with autism. That's 15 times the rate typically found in children.
MONDAY, June 24, 2019 -- The indication for a cystic fibrosis treatment, Symdeko (tezacaftor/ivacaftor) tablets, has been expanded to treat children ages 6 years and older with cystic fibrosis and certain genetic mutations, the U.S. Food and Drug Administration announced today.
Symdeko is approved to treat patients with two copies of the F508del mutation, the most common type of mutation, and patients who have at least one of the mutations in the CFTR gene that is responsive to the active ingredients in Symdeko. The FDA approved Symdeko last year for treatment in children ages 12 years and older with the same genetic mutations. Dosage in children ages 6 to 12 years weighing less than 30 kg is one tablet of 50 mg tezacaftor and 75 mg ivacaftor in the morning and one tablet of 75 mg ivacaftor approximately 12 hours later. In patients aged 12 years and older or who weigh 30 kg or more, dosage is one tablet containing 100 mg tezacaftor and 150 mg ivacaftor and a tablet containing 150 mg ivacaftor 12 hours later.